Anixa Biosciences Inc (ANIX)

Sep 25, 2026

Anixa Biosciences Director Lewis Titterton Jr. recently purchased 49,036 shares of ANIX stock for approximately $131,907, increasing his total holdings to over 1 million shares. Despite this insider buying, the stock has been trading near its 52-week low, and analyst sentiment is mixed, with a consensus "Hold" rating and a target price significantly higher than the current market price. The company reported earnings that met analyst expectations, with a projected full-year loss of $0.31 per share.

Sep 25, 2026

Anixa Biosciences Inc (ANIX) Director Titterton Lewis H jr purchased 49,036 shares of the company's stock on September 23, 2026, increasing his total holdings to over one million shares. This latest transaction continues a pattern of insider accumulation, with Titterton Lewis H jr having bought 76,669 shares in the past year with no sales, and the company seeing 15 insider buys versus 0 sells. The stock was trading at $2.69 at the time of purchase, and while insider buying is a positive signal, investors are advised to consider the company's pipeline progress and financial position, especially given it's a clinical-stage biotech.

Sep 22, 2026

HC Wainwright has lowered its price target for Anixa Biosciences (NASDAQ:ANIX) from $7.00 to $6.00 but maintained a "buy" rating, implying a potential 121% upside. Despite a mixed analyst sentiment leading to an overall "Hold" consensus and an $8.00 average price target, the company met earnings estimates with a quarterly EPS of $(0.08). Insiders have shown confidence by purchasing shares, and institutional investors hold a significant portion of the company's stock.

Sep 22, 2026

Anixa Biosciences Inc. has secured an Australian patent for its breast cancer vaccine technology, extending its intellectual property protection in the region until 2040. This development addresses a critical unmet medical need, as no preventive breast cancer vaccines are currently approved globally. Despite its high Price-to-Sales ratio and unprofitability, the company sees confidence from insiders, with $0.3 million in net insider purchases over the past year.

Sep 20, 2026

Anixa Biosciences Inc (NASDAQ:ANIX) has received a consensus "Hold" rating from five analysts, with an average 12-month price target of $10.00, significantly higher than its current price of $2.77. The company matched analyst expectations with a quarterly EPS of -$0.08 and analysts project a full-year EPS loss of $0.31. Insider and institutional buying has been noted, with insiders purchasing 44,188 shares in the last 90 days and institutions owning 29.13% of the company.

Sep 14, 2026

Anixa Biosciences (NASDAQ:ANIX) Director Lewis Titterton Jr. recently purchased 10,000 shares of the company's stock for $27,300, increasing his direct ownership to 996,967 shares. This transaction comes as ANIX reported quarterly EPS of negative $0.08, meeting analyst expectations, and analysts project a full-year loss of $0.31 per share. The stock currently holds a consensus "Hold" rating with a $10.00 price target.